B cells in rheumatoid arthritis: from hypothesis to the clinic.

@article{Keystone2005BCI,
  title={B cells in rheumatoid arthritis: from hypothesis to the clinic.},
  author={Edward Clark Keystone},
  journal={Rheumatology},
  year={2005},
  volume={44 Suppl 2},
  pages={ii8-ii12}
}
Rituximab (MabThera/Rituxan) is a therapeutic monoclonal antibody against CD20, an antigen expressed by B cells but not B-cell progenitor or plasma cells. It is currently approved for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) and is well tolerated and efficacious. A small open-label study (conducted by Edwards and Cambridge) indicated that selective depletion of B cells using rituximab led to sustained benefits for patients with active rheumatoid arthritis. A… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.

Journal of infusion nursing : the official publication of the Infusion Nurses Society • 2011

Similar Papers

Loading similar papers…